がん研究のアーカイブ

  • ISSN: 2254-6081
  • ジャーナル h-index: 13
  • 雑誌引用スコア: 3.58
  • ジャーナルのインパクトファクター: 3.12
インデックス付き
  • 中国国家知識基盤 (CNKI)
  • サイテファクター
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • Google スカラー
  • 秘密検索エンジン研究所
このページをシェアする

抽象的な

Inhibition of the Cyclin-Dependent Kinases (CDK) 4/6 as Therapy for Estrogen Receptor Positive Breast Cancer

Aurelio B Castrellon, Steven M Nguyen and Luis E Raez

Endocrine therapy (ET) is the usual first-line therapy for patients with hormone receptor-positive metastatic breast cancer (HR+MBC). However, resistance to ET frequently occurs during the course of treatment. Cellular pathways involved in cell proliferation are targets for new drugs that interfere with development of resistance to ET. Cyclin-dependent kinases (CDKs) are a subgroup of serine/ threonine kinases that play a key role in regulating cell cycle progression. In this review, we discuss the currently approved and under investigation CDK 4/6 inhibitors, in addition to their preclinical data and clinical trials that demonstrated their benefit in the treatment of HR+ breast cancer.